Warfarin, aspirin, or both after myocardial infarction

New England Journal of Medicine

Volumn 347, Issue 13, 2002, Pages 969-974

  Hurlen, Mette ^a   Abdelnoor, Michael ^a   Smith, Pål ^b   Erikssen, Jan ^c   Arnesen, Harald ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b VESTRE VIKEN HOSPITAL TRUST   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBYL E; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART REINFARCTION; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

EID: 0037179656     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa020496     Document Type: Article

References (35)

1. Davies MJ, Woolf N, Robertson WB. Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. Br Heart J 1976;38:659-64.
2. Ridolfi RL, Hutchins GM. The relationship between coronary artery lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis. Am Heart J 1977;93:468-86.
3. Horie T, Sekiguchi M, Hirosawa K. Coronary thrombosis in pathogenesis of acute myocardial infarction: histopathological study of coronary arteries in 108 necropsied cases using serial section. Br Heart J 1978;40:153-61.
4. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
5. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarcfion after myocardial infarction. N Engl J Med 1990;323:147-52.
6. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
7. Asinger RW, Mikell FL, Elsperger J, Hodges M. Incidence of left-ventricular thrombosis after acute transmural myocardial infarction: serial evaluation by two-dimensional echocardiography. N Engl J Med 1981;305: 297-302.
8. Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction: relation of therapeutic benefit to patient's age, sex, and severity of infarction. JAMA 1972;222:541-8.
9. Wasserman AJ, Gutterman LA, Yoe KB, Kemp VE Jr, Richardson DW. Anticoagulants in acute myocardial infarction: the failure of anticoagulants to alter mortality in a randomized series. Am Heart J 1966;71:43-9.
10. Loeliger EA, Hensen A, Kroes F, et al. A double-blind trial of longterm anticoagulant treatment after myocardial infarction. Acta Med Scand 1967;182:549-66.
11. Meuwissen OJAT, Vervoorn AC, Cohen O, Jordan FL, Nelemans FA. Double blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1969;186:361-8.
12. Sørensen OH, Friis T, Jørgensen AW, Jørgensen, MB, Nissen NI. Anticoagulant treatment of acute coronary thrombosis. Acta Med Scand 1969;185:65-72.
13. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction: report of the Sixty Plus Reinfarction Study Research Group. Lancet 1980;2:989-93.
14. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
15. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 1979;2:1313-5.
16. Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study. II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986;7:251-69.
17. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. [Erratum, BMJ 2002;324:141.]
18. Breddin K, Loew D, Lechner K, Uberla K, Walter E. Secondary prevention of myocardial reinfarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 1980;9:325-44.
19. The E.P.S.I.M. Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-8.
20. Julian DG, Chamberlain DA, Pocock SJ. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. BMJ 1996;313:1429-31.
21. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-96.
22. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P, Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002;105:557-63.
23. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67. [Erratum, JAMA 2000;284:45.]
24. Hurlen M, Erikssen J, Smith P, Arnesen H, Rollag A. Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients. J Intern Med 1994;236:299-304.
25. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
26. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41.
27. Nomenclature and criteria for diagnosis of ischemic heart disease: report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979;59:607-9.
28. Self SG, Mauritsen RH. Power/sample size calculations for generalized linear models. Biometrics 1988;44:79-86.
29. Self SG, Mauritsen RH, Ohara J. Power calculations for likelihood ratio tests in generalized linear models. Biometrics 1992;48:31-9.
30. Wichmann BA, Hill ID. An efficient and portable pseudo-random number generator. Appl Stat 1982;31:188-90.
31. Schwartz D. Clinical trials. Paris: Flamarion-Medecine, 1982.
32. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, Calif.: Lifetime Learning, 1982.
33. Lee ET. Statistical methods for survival data analysis. Belmont, Calif.: Lifetime Learning, 1980.
34. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyons, France: International Agency for Research on Cancer, 1980. (IARC scientific publications no. 32.)
35. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.